Diffuse Large B-cell Lymphoma Prognosis (NCCN-IPI)

Estimate prognosis in diffuse large B-cell lymphoma


The original International Prognostic Index (IPI) was developed and validated prior to the addition of rituximab to curative anthracycline-based chemotherapy.

Clinical trials have confirmed that rituximab improves the survival of individuals with diffuse large B-cell lymphoma. Using a database of patients treated in the rituximab era (the National Comprehensive Cancer Network database consisting of 1935 patients), this enhanced IPI score is able to discriminate individuals based on 5 clinical predictors (and an 8 point scoring system).

The final score is able to differentiate patients into four distinct prognostic groups for overall survival (low, low-intermediate, high-intermediate, and high risk).

The original IPI was developed by Shipp et al.

The enhanced NCCN-IPI offers improved discrimination for the overall survival of low- and high-risk patients in the rituximab era.


Shipp et al.

New England Journal of Medicine 1993 September 30, 329 (14): 987-94

The Diffuse Large B-cell Lymphoma Prognosis (NCCN-IPI) calculator is created by QxMD.

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Age

0/5 completed